Missed Diagnosis

Hyperaldosteronism combined with hypercortisolaemia in a patient with adrenal carcinoma

N.S. Panesar,¹ S.Y. Tsao,² M.J. Wheeler³ and C.S. Cockram⁴

Departments of ¹Chemical Pathology, ²Clinical Oncology and ⁴Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, and ³Department of Chemical Pathology, St Thomas' Hospital, London SE1 7EH, UK.

Summary: A patient with adrenal carcinoma who initially presented with features suggestive of Conn's syndrome, but subsequently was shown to produce excess cortisol and other steroids, is described.

Introduction

We report on a patient with adrenal carcinoma who presented with features suggesting Conn's syndrome in whom coexistent hypercortisolaemia was subsequently demonstrated. Malignant adrenal tumours may secrete a number of different biologically active steroids and it is known that functional adrenal carcinoma producing Cushing's syndrome can also lead to virilization.¹ In such patients hypercortisolaemia is more likely to be diagnosed and coincident hyperaldosteronism may be overlooked.

Case report

A 69 year old Chinese housewife presented to another hospital with a single grand mal convulsion and generalized muscle weakness in November 1984. Her blood pressure was 170/90 mm Hg. At presentation investigation revealed (reference ranges in parentheses): sodium (Na): 141 mmol/l (135–145), potassium (K): 1.6 mmol/l (3.4–5.2), chloride: 84 mmol/l (95–105), bicarbonate: 33 mmol/l (24–31), urea: 2.8 mmol/l (3.3–7.0) and creatinine: 59 μ mol/l (60–120). The urinary excretion of Na and K were 232 mmol and 42 mmol per 24 hours, respectively. Plasma aldosterone was 0.86 nmol/l (reference range and posture not known) and the morning and evening plasma cortisol concentrations were

345 nmol/l (200–690) and 226 nmol/l (<200), respectively. On the basis of these results Conn's syndrome was diagnosed. Treatment with spironolactone (100 mg/day) partially corrected the hypokalaemia. Computed tomographic (CT) scanning revealed a left adrenal tumour and 2 cysts in the right kidney. A 20 g tumour measuring 5 $\times$ 4 $\times$ 3 cm was subsequently excised and the histological findings were reported to show a cortical adenoma with no overt features of malignancy and no vascular invasion. Post-operatively the blood pressure and plasma potassium concentration returned to normal without treatment.

In July 1985 she developed a mass on the left chest wall. Biopsy revealed metastatic carcinoma consistent with an adrenal primary. In November 1985 she was transferred to the Prince of Wales Hospital for further management. At this time her blood pressure was 180/90 mm Hg on no therapy, plasma K was 2.7 mmol/l (3.5–5.1) and Na 146 mmol/l (134–145). The urinary K was 93 mmol/24 hours. Examination revealed a hard 10 $\times$ 8 cm mass over the left chest wall, 6 cm hepatomegaly and a mass in the left upper quadrant of the abdomen. There were no clinical features to suggest Cushing's syndrome. CT scan at this time showed a large irregular mass in the left suprarenal region involving the body wall. The left kidney was displaced and invaded by the tumour. The spleen and tail of pancreas were also possibly invaded. There were multiple hypodense areas in the liver

Correspondence: N.S. Panesar Ph.D.

Accepted: 30 September 1987

compatible with metastases. Two cysts were again noted in the right kidney and appeared benign. Further endocrinological investigation revealed the following: (i) Elevated plasma cortisol with loss of diurnal rhythm (710 nmol/l, normal 138–690, and 810 nmol/l, normal 69–345, in the morning and evening respectively). Dexamethasone (2 mg/day) failed to suppress morning cortisol levels (670 and 671 nmol/l before and after dexamethasone respectively). ACTH was undetectable. (ii) The supine and erect concentrations of aldosterone were 2.56 nmol/l (0.028–0.445) and 2.70 nmol/l (0.111–0.862) respectively. The commercial aldosterone assay used (Diagnostic Products Corporation, Los Angeles, USA) cross-reacts only minimally with corticosterone, 18-OH-corticosterone and 11-deoxycorticosterone (0.002%, 0.033% and 0.006%, respectively). The plasma renin activities (PRA) were 0.55 ng/ml/h (0.12–1.59) and 0.70 ng/ml/h (0.15–2.12) respectively. Salt loading had no effect on plasma aldosterone or PRA. (iii) The concentrations of other steroids were dehydroepiandrosterone sulphate (DHAS) 10.6 μ mol/l (0.4–4.7-postmenopausal), progesterone 17 nmol/l (<5-follicular phase), 17 α -OH progesterone 7.3 nmol/l (1.7–5.7-follicular phase), androstenedione 5.9 nmol/l (4.4–10.4-premenopausal range) and testosterone 0.9 nmol/l (0.8–3.2). Urinary excretion of 17-oxosteroids and 17-oxogenic steroids was 108 μ mol/day (20.8–52.1) and 176 μ mol/day (10.4–52.1), respectively. Both failed to suppress with dexamethasone.

Treatment was commenced with metyrapone (with dexamethasone cover) and spironolactone. Chemotherapy was given using cisplatin and 5-fluorouracil by infusion. After two courses there was regression of both the chest wall mass and the hepatomegaly and local external radiotherapy was then commenced to the tumour bulk. However, the patient's condition subsequently deteriorated and she died following an episode of pneumonia and septicaemia. Permission for post-mortem was refused.

Discussion

Although the initial presentation suggested Conn's syndrome secondary to an adrenal adenoma, subsequent events demonstrated that the adrenal tumour was malignant. This once again emphasizes

the importance of resection of these tumours, the difficulties of making a histological diagnosis of malignancy if vascular invasion is not demonstrated, and the increased likelihood of malignancy if the tumour is large at demonstration.

Once the tumour had metastasized biochemical investigation showed excess secretion of the Δ^4 pathway steroids – cortisol, progesterone, 17 α -OH progesterone and the Δ^5 pathway intermediate – DHAS. Androstenedione concentration would also appear to be elevated in view of the fact that there is an almost 50% decrease in androstenedione concentration following the menopause.² Thus the urinary excretion of 17-oxosteroid and 17-oxogenic (17-OGS) steroids was elevated. Testosterone concentration, however, remained normal. In keeping with increased secretion along the Δ^4 pathway, aldosterone concentration was also elevated.

There have been several isolated case reports describing excessive secretion of various adrenocortical steroids and intermediates in association with adrenal carcinoma. Brooks *et al.*³ reported a case of primary hyperaldosteronism caused by adrenal carcinoma which was found to excrete excess 17-OGS despite normal secretion of cortisol. The authors ascribed the excess 17-OGS excretion to pregnanetriol and tetrahydro-11-deoxycortisol. Filipecki *et al.*⁴ also reported a case of adrenal carcinoma where there was an excess excretion of aldosterone and 'free corticoids'. More recently, Drury *et al.*⁵ reported two patients with adrenal carcinoma and hypercortisolaemia in both of whom secretion of corticosterone was also elevated. However, in one of these patients, PRA was raised. As with our patient neither of these patients developed clinical features of Cushing's syndrome and they presented with hypertension, hypokalaemia and encephalopathy.

Conn's syndrome secondary to adrenal carcinoma is rare. However, when the situation does arise mineralocorticoids seem to be elaborated initially, followed later by indiscriminate production of glucocorticoids⁶ and androgens, by the tumour. Adrenal carcinoma frequently presents with features of excess glucocorticoid and androgen secretion and evidence of excess mineralocorticoid secretion is not then usually sought. This may partially explain the apparent rarity of Conn's syndrome in association with malignant adrenal tumours.

References

1. Bertagna, C. & Orth, D.N. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). *Am J Med* 1981, 71: 855–874.
2. Judd, H.L., Lucas, W.I. & Yen, S.S.C. Effect of oophorectomy on circulating testosterone and androstenedione levels in patients with endometrial cancer. *Am J Obstet Gynecol* 1972, 118: 793–798.

3. Brooks, R.V., Felix-Davies, D., Radcliffe Lee, M. & Robertson, P.W. Hyperaldosteronism from adrenal carcinoma. *Br Med J* 1972, **1**: 220–221.
4. Filipecki, S., Feltynowski, T. & Poplawska, W. *et al.* Carcinoma of the adrenal cortex with hyperaldosteronism. *J Clin Endocrinol Metab* 1972, **35**: 225–229.
5. Drury, P.L., Edwards, C.R.W., O'Hare, M.J. & Besser, G.M. Two cases of predominantly corticosterone-secreting adrenocortical carcinomas. *J Endocrinol* 1986, **108**: (Suppl.) Abstract no. 271.
6. Artega, E., Biglieri, E.G., Kater, C.E., Lopez, J.M. & Schambelan, M. Aldosterone-producing adrenocortical carcinoma. *Ann Int Med* 1984, **101**: 316–321.